Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768637 | 0.84 | CTBP2 (0.49) | CTBP2ALDH1A1MAPTKDM4EMAPK1 | |
| SCHEMBL17204261 | 0.83 | CTBP2 (0.48) | CTBP2ALDH1A1MAPTKDM4ETAAR1 | |
| SCHEMBL17204262 | 0.83 | CTBP2 (0.48) | CTBP2ALDH1A1MAPTKDM4ETAAR1 | |
| SCHEMBL30172840 | 0.83 | CTBP2 (0.48) | CTBP2ALDH1A1MAPTKDM4ETAAR1 | |
| SCHEMBL7640178 | 0.78 | CTBP2 (0.54) | CTBP2ALDH1A1MAPTKDM4EMAPK1 | |
| SCHEMBL511950 | 0.78 | POLB (0.56) | CTBP2ALDH1A1MAPTKDM4EMAPK1 | |
| SCHEMBL29640755 | 0.78 | POLB (0.56) | CTBP2ALDH1A1MAPTKDM4EMAPK1 | |
| SCHEMBL6897029 | 0.77 | CES2 (0.54) | ALDH1A1MAPTKDM4EMAPK1TSHR | |
| SCHEMBL3175855 | 0.76 | CTBP2 (0.57) | CTBP2ALDH1A1TAAR1MEN1KMT2A | |
| SCHEMBL3179500 | 0.73 | CTBP2 (0.49) | CTBP2ALDH1A1TAAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649093-B2 | (2E)-3-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]-2-propenoic acid; menopausal or postmenopausal disorders, vasomotor symptoms, vaginal atrophy, atrophic vaginitis, endometriosis, female sexual dysfunction, breast cancer, depression, diabetes, osteoporosis | Glaxo Smith Kline LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-11-29 | — | — | US | disclosed |
| EP-1773750-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006002185-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GPER1, ESR2, ESR1 | CTBP2 2378/4885ALDH1A1 586/4885MAPT 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.